Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts

Dec 3, 2024

The discussion kicks off with insights into Jay Bhattacharya's potential leadership at the NIH and its implications for the biopharma industry. The hosts delve into the exciting advancements in multi-targeted CAR T therapies, aiming to tackle solid tumors more effectively. They also highlight the latest FDA approval trends, showcasing biotech's growing independence in getting drugs approved. Additionally, they touch on Novartis' hefty investment in Huntington's disease therapy, signaling strategic moves expected to influence the industry.

Ask episode

Chapters

Transcript

Episode notes

Intro

00:00 • 2min

Controversy and Consequences of the Great Barrington Declaration

01:37 • 5min

Restructuring NIH: Challenges and Opportunities

06:09 • 5min

Exploring Innovations in CAR-T Therapy Targeting

11:21 • 4min

Advancements in CAR-T Therapies and Biotech Independence

15:32 • 10min

Novartis' Bold Investment in Huntington's Disease Therapy

25:45 • 2min